Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo

Du,Jia; Wang,Xiu-Feng; Zhou,Qian-Mei; Zhang,Tian-Ling; Lu,Yi-Yu; Zhang,Hui; Su,Shi-Bing

doi:10.3892/or.2013.2498

Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo

Authors:
- Jia Du
- Xiu-Feng Wang
- Qian-Mei Zhou
- Tian-Ling Zhang
- Yi-Yu Lu
- Hui Zhang
- Shi-Bing Su
View Affiliations

Affiliations: Research Center for Traditional Chinese Medicine Complexity System, Shanghai University of Traditional Chinese Medicine, Pudong, Shanghai 201203, P.R. China
Published online on: May 27, 2013 https://doi.org/10.3892/or.2013.2498
Pages: 685-694

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer remains the leading cause of cancer-related deaths among women. Owing to high efficiency and low toxic effects, further exploration of natural compounds from Chinese herbal medicine may be an efficient approach for breast cancer drug discovery. In this study, we investigated the effects of evodiamine on the growth and metastasis of MDA-MB-231 human breast cancer cells in vitro and in vivo. In vitro, evodiamine inhibited cell migration and invasion abilities through downregulation of MMP-9, urokinase-type plasminogen activator (uPA) and uPAR expression. Evodiamine-induced G0/G1 arrest and apoptosis were associated with a decrease in Bcl-2, cyclin D1 and cyclin-dependent kinase 6 (CDK6) expression and an increase in Bax and p27Kip1 expression. Moreover, evodiamine regulated p-ERK and p-p38 MAPK expression. Evodiamine-induced apoptosis was enhanced by its combination with the extracellular signal-regulated kinase (ERK) inhibitor PD98059 or the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580. Evodiamine-inhibited metastasis was partly blocked by combination with PD98059 or SB203580. In vivo, the administration of evodiamine (10 mg/kg) significantly reduced tumor growth and pulmonary metastasis. These results demonstrate that evodiamine possesses antitumor activities via inhibition of cell migration and invasion, arrest of the cell cycle and induction of cell apoptosis in MDA-MB-231 cells.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Weinberg RA: How cancer arises. Sci Am. 275:62–70. 1996. View Article : Google Scholar
3	Weigelt B, Peterse JL and van’t Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer. 5:591–602. 2005. View Article : Google Scholar : PubMed/NCBI
4	Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J and Piccart M: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of cancer randomized study with cross-over. J Clin Oncol. 18:724–733. 2000.PubMed/NCBI
5	Garcia-Carbonero R and Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 8:641–661. 2002.PubMed/NCBI
6	Galano G, Caputo M, Tecce MF and Capasso A: Efficacy and tolerability of vinorelbine in the cancer therapy. Curr Drug Saf. 6:185–193. 2011. View Article : Google Scholar : PubMed/NCBI
7	Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y and Kamiya T: Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med. 67:628–633. 2001. View Article : Google Scholar : PubMed/NCBI
8	Dai JP, Li WZ, Zhao XF, Wang GF, Yang JC, Zhang L, Chen XX, Xu YX and Li KS: A drug screening method based on the autophagy pathway and studies of the mechanism of evodiamine against influenza A virus. PLoS One. 7:e427062012. View Article : Google Scholar : PubMed/NCBI
9	Rang WQ, Du YH, Hu CP, Ye F, Xu KP, Peng J, Deng HW and Li YJ: Protective effects of evodiamine on myocardial ischemia-reperfusion injury in rats. Planta Med. 70:1140–1143. 2004. View Article : Google Scholar : PubMed/NCBI
10	Lin H, Tsai SC, Chen JJ, Chiao YC, Wang SW, Wang GJ, Chen CF and Wang PS: Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism. 48:1532–1535. 1999. View Article : Google Scholar : PubMed/NCBI
11	Zhang C, Fan X, Xu X, Yang X, Wang X and Liang HP: Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells. Anticancer Drugs. 21:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kan SF, Huang WJ, Lin LC and Wang PS: Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004. View Article : Google Scholar : PubMed/NCBI
13	Chen MC, Yu CH, Wang SW, Pu HF, Kan SF, Lin LC, Chi CW, Ho LL, Lee CH and Wang PS: Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J Cell Biochem. 110:1495–1503. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yang ZG, Chen AQ and Liu B: Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205). Chem Biodivers. 6:924–933. 2009. View Article : Google Scholar : PubMed/NCBI
15	Ogasawara M, Matsubara T and Suzuki H: Screening of natural compounds for Inhibitory activity on colon cancer cell migration. Biol Pharm Bull. 24:720–723. 2001. View Article : Google Scholar : PubMed/NCBI
16	Ogasawara M, Matsunaga T, Takahashi S, Saiki I and Suzuki H: Anti-invasive and metastatic activities of evodiamine. Biol Pharm Bull. 25:1491–1493. 2002. View Article : Google Scholar : PubMed/NCBI
17	Ogasawara M, Matsubara T and Suzuki H: Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol Pharm Bull. 24:917–920. 2001. View Article : Google Scholar : PubMed/NCBI
18	Takada Y, Kobayashi Y and Aggarwal BB: Evodiamine abolishes constitutive and inducible NF-κB activation by inhibiting IκBα kinase activation, thereby suppressing NF-κB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem. 280:17203–17212. 2005.PubMed/NCBI
19	Zhou WH, Du MR, Dong L, Zhu XY, Yang JY, He YY and Li DJ: Cyclosporin A increases expression of matrix metalloproteinase 9 and 2 and invasiveness in vitro of the first-trimester human trophoblast cells via the mitogen-activated protein kinase pathway. Hum Reprod. 22:2743–2750. 2007. View Article : Google Scholar
20	Köhrmann A, Kammerer U, Kapp M, Dietl J and Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer. 9:1882009.PubMed/NCBI
21	Ulisse S, Baldini E, Sorrenti S and D’Armiento M: The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 9:32–71. 2009. View Article : Google Scholar : PubMed/NCBI
22	Han B, Nakamura M, Mori I, Nakamura Y and Kakudo K: Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 14:105–112. 2005.PubMed/NCBI
23	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hunter T and Pines J: Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell. 79:573–582. 1994. View Article : Google Scholar : PubMed/NCBI
25	Zhang Y, Zhang QH, Wu LJ, Tashiro S, Onodera S and Ikejima T: Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa. J Asian Nat Prod Res. 6:19–27. 2004. View Article : Google Scholar : PubMed/NCBI
26	Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–332. 1993.PubMed/NCBI
27	Wu GS: Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev. 26:579–585. 2007. View Article : Google Scholar : PubMed/NCBI
28	Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
29	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
30	Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M, Wiman B and Linder S: ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis. 17:649–654. 1999. View Article : Google Scholar : PubMed/NCBI
31	You J, Mi D, Zhou X, Qiao L, Zhang H, Zhang X and Ye L: A positive feedback between activated extracellularly regulated kinase and cyclooxygenase/lipoxygenase maintains proliferation and migration of breast cancer cells. Endocrinology. 150:1607–1617. 2009. View Article : Google Scholar
32	Li T, Feng Z, Jia S, Wang W, Du Z, Chen N and Chen Z: Daintain/AIF-1 promotes breast cancer cell migration by up-regulated TNF-α via activate p38 MAPK signaling pathway. Breast Cancer Res Treat. 131:891–898. 2012.PubMed/NCBI
33	Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
34	Zhang Y, Zhang QH, Wu LJ, Shin-Ichi Tashiro, Satoshi O and Takashi I: Regulation of ERK MAPK in evodiamine-induced A375-S2 cell death. Chin J Pathophysiol. 20:2175–2179. 2004.
35	Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R and Lin MF: ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer. 107:478–485. 2003. View Article : Google Scholar : PubMed/NCBI
36	Fiddes RJ, Janes PW, Sivertsen SP, Sutherland RL, Musgrove EA and Daly RJ: Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene. 16:2803–2813. 1998. View Article : Google Scholar
37	Boldt S, Weidle UH and Kolch W: The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis. 23:1831–1838. 2002. View Article : Google Scholar : PubMed/NCBI
38	Porras A, Zuluaga S, Black E, Valladares A, Alvarez AM, Ambrosino C, Benito M and Nebreda AR: P38α mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell. 15:922–933. 2004.